Posted by Michael Wonder on 16 Apr 2020
Bayer's chloroquine donation to U.S. raises concern about FDA standards in pandemic
16 April 2020 - On March 21, two days after President Donald Trump first touted chloroquine drugs as a “game changer” in the fight against COVID-19, administration officials privately described what they felt was a “win” in the president’s efforts to build an emergency stockpile of the drugs: a hefty donation of pills from Bayer.
In an exchange of enthusiastic emails among federal health officials reviewed by Reuters, Keagan Lenihan, chief of staff of the U.S. FDA, cautioned that “3-4 days” of testing would be needed.
“Potentially serious issues with product so let’s be careful when we take that win,” she wrote.
